Everolimus in Anaplastic Thyroid Cancer: A Case Series
Background: Anaplastic thyroid cancer (ATC) is a very aggressive disease and accounts for over 50% of thyroid-cancer related deaths. mTOR inhibition has shown anti-tumor activity in ATC. We report our experience treating patients with ATC with everolimus off-protocol.Methods: Patients with confirmed...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.00106/full |
| _version_ | 1818911445823258624 |
|---|---|
| author | Ethan J. Harris Glenn J. Hanna Nicole Chau Guilherme Rabinowits Robert Haddad Danielle N. Margalit Jonathan Schoenfeld Roy B. Tishler Justine A. Barletta Matthew Nehs Pasi Janne Julian Huang Julian Huang Phillip Groden Alec Kacew Jochen Lorch |
| author_facet | Ethan J. Harris Glenn J. Hanna Nicole Chau Guilherme Rabinowits Robert Haddad Danielle N. Margalit Jonathan Schoenfeld Roy B. Tishler Justine A. Barletta Matthew Nehs Pasi Janne Julian Huang Julian Huang Phillip Groden Alec Kacew Jochen Lorch |
| author_sort | Ethan J. Harris |
| collection | DOAJ |
| description | Background: Anaplastic thyroid cancer (ATC) is a very aggressive disease and accounts for over 50% of thyroid-cancer related deaths. mTOR inhibition has shown anti-tumor activity in ATC. We report our experience treating patients with ATC with everolimus off-protocol.Methods: Patients with confirmed ATC and treated with everolimus at DFCI were identified and reviewed retrospectively. NexGen sequencing was performed, and radiologic responses were correlated with mutational profile.Results: Five patients were treated from 2013 to 2016. Three patients had a response, which included one patient who achieved a partial response for 27.9 months, and two patients who had stable disease for 3.7 and 5.9 months, respectively. Genomic analysis was available in two patients and revealed that the partial responder had mutations involving the PI3K/mTOR pathway.Conclusion: Everolimus has anti-tumor activity in ATC, and responses may correlate with mutations involving the PI3K/mTOR pathway. Further studies are warranted. |
| first_indexed | 2024-12-19T22:58:49Z |
| format | Article |
| id | doaj.art-6f6a1d011531446f99dae295c4c010ad |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-19T22:58:49Z |
| publishDate | 2019-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-6f6a1d011531446f99dae295c4c010ad2022-12-21T20:02:34ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2019-02-01910.3389/fonc.2019.00106429986Everolimus in Anaplastic Thyroid Cancer: A Case SeriesEthan J. Harris0Glenn J. Hanna1Nicole Chau2Guilherme Rabinowits3Robert Haddad4Danielle N. Margalit5Jonathan Schoenfeld6Roy B. Tishler7Justine A. Barletta8Matthew Nehs9Pasi Janne10Julian Huang11Julian Huang12Phillip Groden13Alec Kacew14Jochen Lorch15Dana-Farber Cancer Institute, Boston, MA, United StatesDana-Farber Cancer Institute, Boston, MA, United StatesDana-Farber Cancer Institute, Boston, MA, United StatesMiami Cancer Institute, Miami, FL, United StatesDana-Farber Cancer Institute, Boston, MA, United StatesDana-Farber Cancer Institute, Boston, MA, United StatesDana-Farber Cancer Institute, Boston, MA, United StatesDana-Farber Cancer Institute, Boston, MA, United StatesBrigham and Women's Hospital, Boston, MA, United StatesBrigham and Women's Hospital, Boston, MA, United StatesDana-Farber Cancer Institute, Boston, MA, United StatesDana-Farber Cancer Institute, Boston, MA, United StatesYale School of Medicine, New Haven, CT, United StatesIcahn School of Medicine at Mount Sinai, New York, NY, United StatesDana-Farber Cancer Institute, Boston, MA, United StatesDana-Farber Cancer Institute, Boston, MA, United StatesBackground: Anaplastic thyroid cancer (ATC) is a very aggressive disease and accounts for over 50% of thyroid-cancer related deaths. mTOR inhibition has shown anti-tumor activity in ATC. We report our experience treating patients with ATC with everolimus off-protocol.Methods: Patients with confirmed ATC and treated with everolimus at DFCI were identified and reviewed retrospectively. NexGen sequencing was performed, and radiologic responses were correlated with mutational profile.Results: Five patients were treated from 2013 to 2016. Three patients had a response, which included one patient who achieved a partial response for 27.9 months, and two patients who had stable disease for 3.7 and 5.9 months, respectively. Genomic analysis was available in two patients and revealed that the partial responder had mutations involving the PI3K/mTOR pathway.Conclusion: Everolimus has anti-tumor activity in ATC, and responses may correlate with mutations involving the PI3K/mTOR pathway. Further studies are warranted.https://www.frontiersin.org/article/10.3389/fonc.2019.00106/fullanaplastic thyroid cancer (ATC)precision medicinemTOR inhibition in head and neck cancerexceptional responderPI3K mTOR |
| spellingShingle | Ethan J. Harris Glenn J. Hanna Nicole Chau Guilherme Rabinowits Robert Haddad Danielle N. Margalit Jonathan Schoenfeld Roy B. Tishler Justine A. Barletta Matthew Nehs Pasi Janne Julian Huang Julian Huang Phillip Groden Alec Kacew Jochen Lorch Everolimus in Anaplastic Thyroid Cancer: A Case Series Frontiers in Oncology anaplastic thyroid cancer (ATC) precision medicine mTOR inhibition in head and neck cancer exceptional responder PI3K mTOR |
| title | Everolimus in Anaplastic Thyroid Cancer: A Case Series |
| title_full | Everolimus in Anaplastic Thyroid Cancer: A Case Series |
| title_fullStr | Everolimus in Anaplastic Thyroid Cancer: A Case Series |
| title_full_unstemmed | Everolimus in Anaplastic Thyroid Cancer: A Case Series |
| title_short | Everolimus in Anaplastic Thyroid Cancer: A Case Series |
| title_sort | everolimus in anaplastic thyroid cancer a case series |
| topic | anaplastic thyroid cancer (ATC) precision medicine mTOR inhibition in head and neck cancer exceptional responder PI3K mTOR |
| url | https://www.frontiersin.org/article/10.3389/fonc.2019.00106/full |
| work_keys_str_mv | AT ethanjharris everolimusinanaplasticthyroidcanceracaseseries AT glennjhanna everolimusinanaplasticthyroidcanceracaseseries AT nicolechau everolimusinanaplasticthyroidcanceracaseseries AT guilhermerabinowits everolimusinanaplasticthyroidcanceracaseseries AT roberthaddad everolimusinanaplasticthyroidcanceracaseseries AT daniellenmargalit everolimusinanaplasticthyroidcanceracaseseries AT jonathanschoenfeld everolimusinanaplasticthyroidcanceracaseseries AT roybtishler everolimusinanaplasticthyroidcanceracaseseries AT justineabarletta everolimusinanaplasticthyroidcanceracaseseries AT matthewnehs everolimusinanaplasticthyroidcanceracaseseries AT pasijanne everolimusinanaplasticthyroidcanceracaseseries AT julianhuang everolimusinanaplasticthyroidcanceracaseseries AT julianhuang everolimusinanaplasticthyroidcanceracaseseries AT phillipgroden everolimusinanaplasticthyroidcanceracaseseries AT aleckacew everolimusinanaplasticthyroidcanceracaseseries AT jochenlorch everolimusinanaplasticthyroidcanceracaseseries |